PSA-Stratified Performance of [¹⁸F]DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer Patients under Androgen Deprivation Therapy.

ABSTRACT: Based on in vitro studies, it is known that androgen deprivation therapy (ADT) increases prostate-specific membrane antigen (PSMA) expression on prostate cancer (PCa) cells. However, ADT also has cytoreductive effects which can decrease lesion size. The present evaluation was conducted to further analyze the influence of ongoing ADT on [18F]DCFPyL positron emission tomography/computed tomography (PET/CT) performance in the setting of biochemically recurrent PCa. We retrospectively evaluated two groups of PCa patients, previously treated with radical intent, who had undergone [18F]DCFPyL PET/CT because of biochemical relapse with a minimum PSA level of 0.4 ng/mL. One group consisted of 95 patients under ADT at the time of the PET examination, and the other consisted of 445 patients not rece

SUBMITTER: Harsini S 

PROVIDER: S-EPMC9498260 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature